Daniel Herchenhorn

Daniel Herchenhorn


Over the last 20 years, I have dedicated myself, through clinical research and translational studies, to the development of new therapies in isolation or in combination, with the exploration of biomarkers in solid tumors, especially urological tumors, head and neck tumors and malignant melanoma. I have a group of colleagues made up of a multi-disciplinary team comprising oncologists, radiooncologists, nuclear physicians and others, who help us conduct clinical studies as well as literature reviews. I currently work as an assistant researcher at IDOR, the institute responsible for research, teaching and innovation activities at Rede D’Or São Luiz, as well as being the Scientific Coordinator of the D’Or Oncology Group and Coordinator of the Oncology Residency Program at Oncologia D’Or, Rio de Janeiro. 

Keywords: Urological Tumors; Prostate Cancer; Head and Neck Cancer; Malignant Melanoma. 


PhD in Oncology, USP/SP

Residency in Clinical Oncology, National Cancer Institute

Lancet Oncology Prostate Cancer Committee




Full Member, Academy of Medicine of Rio de Janeiro - AMRJ, AMRJ

Análise Medicina Award, Análise Editorial

Latin America Research Award, Novartis - USA

2001 Lilly Prize for Pharmacogenomics, Eli lilly and Company

Global Prize for Young Researchers, Glym-Ely Lilly- USA

Selected Publications

Werutsky G, Maluf FC, Cronemberger EH, Carrera Souza V, Dos Santos Martins SP, Peixoto F, Smaletz O, Schutz F, Herchenhorn D, Santos T, Mavignier Carcano F, Queiroz Muniz D, Nunes Filho PRS, Zaffaroni F, Barrios C, Fay A. The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels. BMC Cancer. 2019 May 23;19(1):487. PMID: 31122212; PMCID: PMC6533731.
doi: 10.1186/s12885-019-5709-y 

Maluf F, Soares A, Avanço G, Hada AL, Cardoso APG, Carneiro A, Herchenhorn D, Jardim DLF, Schutz FA, Kater FR, Pereira FMT, Monteiro FSM, Morbeck IAP, Reolon JFN, da Trindade KM, Andrade LMQDS, Nogueira LM, Furoni R, Natel RA, Dos Reis RB, Fogace RN, Souza VC. Consensus on diagnosis and management of non-metastatic castration resistant prostate cancer in Brazil: focus on patient, selection, treatment efficacy, side effects and physician’s perception according to patient comorbidities. Int Braz J Urol. 2021 Mar-Apr;47(2):359-373. PMID: 33284538; PMCID: PMC7857750.
doi: 10.1590/S1677-5538.IBJU.2020.0249 

Maluf FC, Pereira FMT, Silva AG, Dettino ALA, Cardoso APG, Sasse AS, Soares A, Kann AG, Herchenhorn D, Jardim DLF, Cortés DEL, Kater FR, Morbeck IAP, Reolon JFN, Rinck JA Jr, Zarbá JJ, Sade JP, da Trindade KM, Costa LAGA, Dos Santos LV, Maia MC, Siqueira MB, Gillessen S. Consensus on the Treatment and Follow-Up for Metastatic Castration-Resistant Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC). JCO Glob Oncol. 2021 Apr;7:559-571. PMID: 33856891; PMCID: PMC8162971.
doi: 10.1200/GO.20.00511 

Treistman N, Nobre GM, Tramontin MY, da Silva GMW, Herchenhorn D, de Lima Araujo LH, de Andrade FA, Corbo R, Bulzico D, Vaisman F. Prognostic factors in patients with advanced differentiated thyroid cancer treated with multikinase inhibitors – a single Brazilian center experience. Arch Endocrinol Metab. 2021 Nov 3;65(4):411-420. Epub 2021 Apr 29. PMID: 33939907.
doi: 10.20945/2359-3997000000364 

Herchenhorn D, Freire V, Oliveira T, Tarouquella J. Sequential therapies for advanced urothelial cancer: Hope meets new challenges. Crit Rev Oncol Hematol. 2021 Apr;160:103248. Epub 2021 Mar 13. PMID: 33727199.
doi: 10.1016/j.critrevonc.2021.103248 

More Content